null

Anti-Human CTLA-4 (Ipilimumab) - Fc Reduced HRP Biosimilar (IVMB0456)

SKU:
IVMB0456
€929
Frequently bought together:

Description

system_update_altDatasheetsystem_update_altMSDS
Product Name:Anti-Human CTLA-4 (Ipilimumab) - HRP
SKU:IVMB0456
Size:100 µg
Antibody Type:Biosimilar Recombinant Human Monoclonal Antibody
Clone:MDX-010
Target:CTLA-4
Isotype:Human IgG1κ
Host Species:Human
Reactivity:Human
Applications:ELISA
Expression Host:HEK-293 Cells
FC Effector Activity:Muted
Synonyms:CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3
Product Concentration:0.5 mg/ml
Immunogen:Human CTLA-4
Applications and Recommended Usage:FC The suggested concentration for Ipilimumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
ELISA
Antigen Distribution:CTLA4 is constitutively expressed in regulatory T cells.
Formulation:This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)
Specificity:This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Ipilimumab. Ipilimumab binds to Human CTLA-4. This product is for research use only.
Additional Reported Applications For Relevant Conjugates:BCyTOF

Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) is a protein receptor that serves as an immune checkpoint and down-regulates the immune system. CTLA-4 is constitutively expressed in regulatory T cells but is only upregulated in conventional T cells following activation. Many cancers, including Melanoma, are associated with CTLA-4 upregulation because the body’s ability to recognize and destroy cancer cells is hampered by an inhibitory mechanism. Ipilimumab targets CTLA-4 and works by turning off this inhibitory mechanism and, thus, enhances the body’s own immune response against cancer cells.”2 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with Nivolumab and Ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.1 This cost-effective, research-grade Anti-Human CTLA-4 (Ipilimumab) utilizes the same variable regions from the therapeutic antibody Ipilimumab making it ideal for research projects.

Regulatory Status:Research Use Only (RUO). Non-Therapeutic.
Storage and Handling:This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C.Do not freeze.
Research Area:Biosimilars

Related Products